Medincell: stock up on positive study data
(CercleFinance.com) - Medincell shares are up 3% after its partner Teva presented new positive data from the initial period of the Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult patients diagnosed with schizophrenia.
This data demonstrates - across several baseline indicators - a significant improvement in social interactions and quality of life between baseline and week eight of the study, the biopharma company says.
The data show that Medincell's subcutaneous administration technology used for olanzapine LAI has not resulted in any post-injection delirium/sedation syndrome (PDSS) events to date, it adds.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This data demonstrates - across several baseline indicators - a significant improvement in social interactions and quality of life between baseline and week eight of the study, the biopharma company says.
The data show that Medincell's subcutaneous administration technology used for olanzapine LAI has not resulted in any post-injection delirium/sedation syndrome (PDSS) events to date, it adds.
Copyright (c) 2024 CercleFinance.com. All rights reserved.